Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 8.42% | 419.05 | 0.0% | $8674.93m | |
| BNTX | BioNTech SE | 17.80% | 414.44 | 0.0% | $1709.63m | |
| NVAX | Novavax, Inc. | 18.69% | 223.81 | 79.8% | $898.59m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -0.92% | 10.72 | 0.7% | $749.37m | |
| AMGN | Amgen, Inc. | -6.46% | 228.31 | 1.3% | $524.03m | |
| BIIB | Biogen, Inc. | 0.03% | 338.10 | 1.7% | $451.97m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.23% | 199.59 | 1.9% | $424.11m | |
| GILD | Gilead Sciences, Inc. | -0.85% | 69.24 | 1.0% | $409.81m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.95% | 580.95 | 2.7% | $330.19m | |
| ILMN | Illumina, Inc. | 1.24% | 504.60 | 3.5% | $271.58m | |
| NTLA | Intellia Therapeutics, Inc. | 5.87% | 146.94 | 2.3% | $204.93m | |
| SGEN | Seagen Inc. | 3.17% | 163.21 | 5.8% | $137.56m | |
| CRSP | CRISPR Therapeutics AG | 2.63% | 124.61 | 0.6% | $137.02m | |
| TBIO | Translate Bio, Inc. | 0.48% | 37.85 | 3.3% | $134.82m | |
| EXAS | EXACT Sciences Corp. | 1.56% | 105.83 | 18.1% | $131.45m |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.